XPOVIO Online Discussion
Interactive clinical discussion:
XPOVIO® (selinexor), Now approved as early as 1st relapse in multiple myeloma.
By: Joseph Mikhael, MD – Translational Genomics Research Institute
Virtual Program
https://tallen-inc.zoom.us/j/93984020923?pwd=QVdmWElmcDlEa0ZQUlAxVCtBa2Jodz09
RSVP:
866-914-9069
KAR0001187 – Please reference this number during registration